The ultimate goal of quality risk management (QRM) is to enable individuals involved in the entire manufacturing product life cycle to make informed decisions to accept, mitigate, or control risks to the patient. Since the publication of the first edition of ICH Q9 in 2005, regulatory documents have been updated periodically to promote the use of QRM principles, and in recent times the word risk has been found to have increased significantly, just think of the ‘current version of Eudralex Volume 4 Annex 1, GMP Manufacturing of sterile and medicinal products when compared to the previous one.
The new version of ICH guideline Q9 (R2), finalized in January 2023, introduces several new key features and updates to improve the risk management process in pharmaceutical quality systems.
The changes aim to address the changing pharmaceutical manufacturing landscape and regulatory expectations. Here are the main new features and updates introduced by ICH guideline Q9 (R2):
Clarification and improvement of risk management principles
- Risk-based approach: the guideline emphasizes a more robust risk-based approach to quality management, clarifying the importance of using risk management throughout the product life cycle.
- Risk communication: improved guidelines on risk communication, ensuring that risks are effectively communicated and understood at all levels of the organization.
Addressing subjectivity in risk assessments
Managing subjectivity: new sections address subjectivity in risk assessments, providing tools and strategies to minimize bias and improve objectivity in risk assessments.
Formalities in quality risk management (QRM)
Appropriate level of formality: the guideline provides more detailed recommendations on the appropriate level of formality in QRM processes, helping organizations determine the rigor and documentation needed based on the complexity and impact of risks.
Enhanced risk review
Risk review process: the guideline now includes improved guidance on the risk review process, encouraging regular review and updating of risk assessments to ensure they remain relevant and effective.
Risk-Based Decisions.
Context for decision making: introduces rules and contexts for making risk-based decisions, ensuring that decisions are systematically justified and documented based on risk assessment.
Risk Management Tools
Selection and application of tools: further guidance on the selection and application of risk management tools, including examples and case studies, to help organizations choose the most appropriate methods for their specific needs.
Integration with pharmaceutical quality systems
Systematic integration: the updated guideline emphasizes the integration of QRM into the overall pharmaceutical quality system, ensuring that risk management is an intrinsic part of all quality processes.
Specific areas of application
Detailed applications: the guideline provides more detailed examples and case studies on the application of QRM to specific areas such as manufacturing, quality control and regulatory submissions.
Risk management in new technologies and innovations
Emerging technologies: new guidelines on the application of the principles of the
QRM to emerging technologies and innovations, ensuring that new processes and products are developed with a solid foundation of risk management.
Improved training and competence
Training programs: recommendations to improve training and competence in QRM for all personnel involved in quality management, ensuring a thorough understanding and effective implementation of QRM principles.
Continuous improvement
Focus on continuous improvement: the guideline places greater emphasis on continuous improvement within the QRM process, encouraging organizations to regularly assess and improve their risk management practices.
These updates reflect the evolving needs of the pharmaceutical industry and regulatory expectations, aiming to improve the robustness and effectiveness of quality risk management in ensuring product quality and patient safety.
The new version of ICH guideline Q9 (R2) provides greater clarity on the concepts of hazard identification and risk identification, helping to distinguish between these two critical components of Quality Risk Management (QRM). Understanding these differences is essential for effective implementation of QRM practices.
These are some of the new issues and updates introduced by the ICH Q9 (R2) guideline that will be explored in more detail in a series of subsequent articles.
Management of subjectivity
Subjectivity in quality risk management is a critical issue that requires careful consideration. Quality risk management (QRM) is a systematic process for assessing, monitoring, communicating, and reviewing risks to the quality of a drug or medicinal product throughout its life cycle. However, subjectivity can influence risk assessments and decision making.
Here are some key points:
Deep knowledge and probability
Deep knowledge plays a significant role in mitigating subjectivity. Whether it is qualitative expert solicitation or structured expert judgments, engaging experts helps create more objective and reliable risk assessments. By relying on experts, organizations can draw on their domain-specific experience and insights, reducing the impact of personal biases.
Risk-based decisions
Risk-based decision making is a fundamental part of QRM. It involves risk assessment based on scientific knowledge rather than personal beliefs or feelings. To minimize subjectivity, organizations should adopt transparent, evidence-based approaches. These could include quantitative risk assessment, statistical models, and data-driven analysis.
Challenges and solutions
Subjectivity arises when assessing risks related to product quality or patient safety. Factors such as individual perspectives, cognitive biases and emotional influences can affect risk assessments. To address this, organizations can:
- standardize risk assessment processes;
- use clear criteria and predefined scales;
- encourage cross-functional collaboration to ensure diverse viewpoints;
- regularly review and update risk assessments to incorporate new information;
- balance objectivity and real-world context.
Although minimizing subjectivity is crucial, balancing it with practical considerations is essential. Real-world complexities often require judgment calls. Organizations should seek a harmonious balance between scientific rigor and practical feasibility.
In summary, controlling subjectivity in risk-based decision making improves the effectiveness of quality risk management. By leveraging expert knowledge, transparent methodologies, and cross-functional collaboration, organizations can make informed decisions that prioritize patient safety and product quality.
